Study S000024

A Single-center, Open-label, Phase Ⅰ Clinical Study of the Absorption, Metabolism, and Excretion of [14C]HRS9531 in Healthy Male Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06855147
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 7
Start: 2025-04-21
Primary completion: 2025-06-17
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Type 2 Diabetes Mellitus; Weight Loss
Interventions: DRUG:[14C]HRS9531
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Maximum concentration (Cmax). [0 to anticipated 64 days.]
Time to reach the maximum concentration (Tmax). [0 to anticipated 64 days.]
Half-life (t1/2). [0 to anticipated 64 days.]
Total radioactive recovery rate in urine. [0 to anticipated 64 days.]
Total radioactive recovery rate in feces. [0 to anticipated 64 days.]
Cumulative radioactive recovery rate in urine. [0 to anticipated 64 days.]
Cumulative radioactive recovery rate in feces. [0 to anticipated 64 days.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.